比较 Domvanalimab 和 Zimberelimab 与 Pembrolizumab 联合治疗未经治疗的局部晚期或转移性 PD-L1-高非小细胞肺癌的研究 (ARC-10)
评估 Zimberelimab (AB122) 联合 AB154 在一线、PD-L1 高、局部晚期或转移性非小细胞肺癌中的 3 期研究
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
研究概览
地位
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
George、南非
- Research Site
-
Johannesburg、南非
- Research Site
-
Pretoria、南非
- Research Site
-
-
-
-
-
Taichung、台湾
- Research Site
-
-
-
-
-
Adana、土耳其(türkiye)
- Research Site
-
Ankara、土耳其(türkiye)
- Research Site
-
Edirne、土耳其(türkiye)
- Research Site
-
Istanbul、土耳其(türkiye)
- Research Site
-
Kocaeli、土耳其(türkiye)
- Research Site
-
-
-
-
-
Bangkok、泰国
- Research Site
-
Changwat Sara Buri、泰国
- Research Site
-
Chanthaburi、泰国
- Research Site
-
Chiang Mai、泰国
- Research Site
-
Khon Kaen、泰国
- Research Site
-
Lampang、泰国
- Research Site
-
Nakhon Nayok、泰国
- Research Site
-
Nakhon Ratchasima、泰国
- Research Site
-
Phitsanulok、泰国
- Research Site
-
Songkhla、泰国
- Research Site
-
Ubon Ratchathani、泰国
- Research Site
-
-
-
-
Georgia
-
Columbus、Georgia、美国、31904
- Research Site
-
-
Texas
-
Kingwood、Texas、美国、77339
- Research Site
-
-
Virginia
-
Blacksburg、Virginia、美国、24060
- Research Site
-
-
-
-
-
Davao City、菲律宾
- Research Site
-
Manila、菲律宾
- Research Site
-
-
-
-
-
Hanoi、越南
- Research Site
-
-
-
-
-
Daegu、韩国
- Research Site
-
Incheon、韩国
- Research Site
-
Jinju、韩国
- Research Site
-
Seoul、韩国
- Research Site
-
Suwon、韩国
- Research Site
-
-
-
-
-
Hong Kong、香港
- Research Site
-
-
-
-
-
Johor Bahru、马来西亚
- Research Site
-
Kuala Lumpur、马来西亚
- Research Site
-
Kuantan、马来西亚
- Research Site
-
Kuching、马来西亚
- Research Site
-
Pulau Pinang、马来西亚
- Research Site
-
Putrajaya、马来西亚
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Histologically confirmed, treatment naïve, locally advanced or metastatic (stage IIIB IV per AJCC version 8), squamous or non-squamous NSCLC with documented high PD L1 expression (TC ≥ 50%) as determined by the VENTANA SP263 IHC assay, as assessed by central laboratories).
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
-
Must have at least 1 measurable lesion per RECIST v1.1
-
Adequate organ and marrow function
-
If a participant has brain or meningeal metastases, the participant must meet the following criteria:
- Have no evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to the first dose.
- Participants with previously treated brain metastases may participate provided they have stable central nervous system (CNS) disease for at least 4 weeks prior to enrollment. Stable CNS disease is defined as resolution of all neurologic symptoms to baseline, having no evidence of new or enlarging brain metastases, and not requiring use of corticosteroids for CNS disease for at least 14 days prior to the start of study treatment. Participants who have had brain metastases resected or have received whole brain radiotherapy ending at least 4 weeks (or stereotactic radiotherapy ending at least 2 weeks) prior to initiation of study treatment are permitted.
- Carcinomatous meningitis is excluded regardless of clinical stability.
Key Exclusion Criteria:
- Presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved by local health authority and available
- Use of any live vaccines against infectious diseases within 28 days of first dose
- Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
- Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
- Prior treatment with any anti-PD-1, anti-PD-L1 or any other antibody targeting an immune checkpoint.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
有源比较器:Arm A - Study Part 1 (Platinum-based Chemotherapy)
Participants will receive carboplatin, pemetrexed, and paclitaxel by intravenous (IV) infusion. |
Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. Participants receive carboplatin, pemetrexed, and paclitaxel at a target area under the curve. |
|
实验性的:Arm B - Study Part 1 (Zimberelimab Monotherapy)
Participants will receive zimberelimab monotherapy by IV infusion. |
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
其他名称:
|
|
实验性的:Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy)
Participants will receive zimberelimab in combination with AB154 by IV infusion. |
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
其他名称:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
其他名称:
|
|
实验性的:Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy)
Participants will receive domvanalimab in combination with zimberelimab by IV infusion. |
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
其他名称:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
其他名称:
|
|
有源比较器:Arm E - Study Part 2 (Pembrolizumab)
Participants will receive pembrolizumab by IV infusion. |
Pembrolizumab is a humanized Immunoglobulin G4 monoclonal antibody targeting the PD-1 receptor |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
无进展生存期 (PFS)
大体时间:从随机分组到全因死亡(最长 7 年)
|
从随机分组到全因死亡(最长 7 年)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
总生存期 (OS)
大体时间:从随机分组到全因死亡(最长 7 年)
|
从随机分组到全因死亡(最长 7 年)
|
|
确认的总体缓解率 (ORR)
大体时间:从随机分组到全因死亡(最长 7 年)
|
从随机分组到全因死亡(最长 7 年)
|
|
出现治疗中出现的不良事件的参与者人数
大体时间:从随机分组到全因死亡(最长 7 年)
|
从随机分组到全因死亡(最长 7 年)
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ARC-10
- 2020-003562-39 (EudraCT编号)
- PHRR210222-003371 (其他标识符:Philippine Health Research Registry)
- 2022-503071-28-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.